SEC Form 4 · accession 0001513162-17-000258
Anixa Biosciences Inc · ANIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Catelani
Officer — Chief Operating Officer
Period of report
Sep 6, 2017
Accepted (ET)
Sep 8, 2017 · 7:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000715446
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock OptionF1,F2 | $4.85 | Sep 6, 2017 | D | 50,000 | D | — | Nov 15, 2026 | Common Stock | 50,000 | 0 | D |
| Employee Stock OptionF1,F2 | $0.67 | Sep 6, 2017 | A | 50,000 | A | — | Nov 15, 2026 | Common Stock | 50,000 | 50,000 | D |
| Employee Stock OptionF1,F3 | $0.96 | Sep 6, 2017 | D | 200,000 | D | — | Jul 6, 2027 | Common Stock | 200,000 | 0 | D |
| Employee Stock OptionF1,F3 | $0.67 | Sep 6, 2017 | A | 200,000 | A | — | Jul 6, 2027 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options.
- F2The option was originally granted on November 15, 2016 and vests one third on November 15, 2017 and two thirds vest quarterly over two years commencing January 31, 2018.
- F3The option was originally granted on July 6, 2017 and vests and become exercisable as follows: 25% on July 6, 2018 and the remainder over twelve (12) equal quarterly installments beginning October 31, 2018.